ground zero opinion from doctor on provenge, page-4

Re costs to doctors,

Also, the American's financial situation is very different to that of Dubai & Australia - maybe not Europe.

I am sure MR stated in the past, that he expects CVAC to be used in other duristictions BEFORE FDA approval in USA.

So, I would see the company's very important job being to negotiate cost/price structures that meet the needs of patients, the company & those using CVAC. After all, it really will meet an unmet need.

My only concern is the cost of setting up manufacturing plants & the passed on costs to whichever consumers use CVAC.

But DNDN appear to have clearly misled investors - one thing I will say about Prima - they have always understated their potential, as opposed to ovestating it - and that has to be looked at as a positive. Even if the chart (TA) doesn't look positive atm.

Spare Paper